Karyopharm outlines potential myelofibrosis approval and launch as early as Q1 2027 while targeting up to ~$1B in U.S. peak revenue — See source for full details.
$KPTI
Price history, market instrument context, member research, and related headlines in one place.
KPTI key statistics
NasdaqGSUSD
52-week range
$0.3150%$10.99
Latest session $0.315–$0.4274Karyopharm Therapeutics Inc. (KPTI) is a stock instrument quoted on NasdaqGS in USD. The most recently published price is $0.315, down $0.11 (26.30%) from the previous close of $0.4274. It has traded between $0.315 and $0.4274 in the latest session. Over the past year it has ranged from $0.315 to $10.99, leaving it trading near the bottom of its 52-week range. Reported volume for the session was 2.1M. Figures are the latest published by the exchange feed and are not a recommendation.
Primary market bars from Yahoo Finance · Extended-hours prints appear when supplied by the venue · Interactive charts powered by TradingView Lightweight Charts™ · Not a recommendation
Source-linked intelligence
Related news
Karyopharm Therapeutics Q2 2026 Earnings Preview — See source for full details.
Karyopharm plummets as Xpovio fails in phase 3 trial for endometrial cancer — See source for full details.
Karyopharm endometrial cancer trial misses primary endpoint — See source for full details.
Karyopharm plans myelofibrosis drug filing in August — See source for full details.
Loading $KPTI research…